Blog
About

  • Record: found
  • Abstract: found
  • Article: not found

Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.

Clinical lymphoma, myeloma & leukemia

pharmacology, Pyrimidines, therapeutic use, Pyrazines, Proteasome Inhibitors, Protease Inhibitors, Piperazines, Pilot Projects, Middle Aged, Male, mortality, drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Humans, Female, Drug Resistance, Boronic Acids, Benzamides, metabolism, drug effects, Basophils, Apoptosis, Aged

Read this article at

ScienceOpenPublisherPMC
Bookmark
      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

      Abstract

      Proteasome inhibitors are anticancer compounds that disrupt the proteolytic activity of the proteasome and lead to tumor cell growth arrest and apoptosis. Bortezomib is a proteasome inhibitor that is currently approved for use in multiple myeloma (MM) and mantle-cell lymphoma. It induces apoptosis of chronic myeloid leukemia (CML) cells in vitro, but the activity of bortezomib in patients with imatinib-resistant CML is unknown. We conducted a pilot trial to evaluate the activity of single-agent bortezomib in CML. Seven patients with imatinib-refractory CML were treated with bortezomib at a dose of 1.5 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. The median number of cycles received was 2. No patient had a hematologic or cytogenetic response. Three patients had a temporary decrease in basophil counts associated with therapy with bortezomib. Six patients experienced grade 3/4 nonhematologic toxicities. Bortezomib had minimal efficacy and considerable toxicity in patients with imatinib-refractory CML. Further studies should focus on alternative approaches to using proteasome inhibitors in the treatment of CML, such as in combination with tyrosine kinase inhibitors (TKIs) or as a strategy to eradicate leukemic stem cells. Copyright © 2011. Published by Elsevier Inc.

      Related collections

      Author and article information

      Journal
      10.1016/j.clml.2011.06.004
      4405186
      21816374

      Comments

      Comment on this article